SCHEMBL30730640

SCHEMBL30730640

Cc1nccnc1CC(=O)N1CCC(c2nc(C3CCCCC3)no2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.46
CPT1A P50416 2/20 0.43
CPT2 P23786 1/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
SMO Q99835 2/20 0.40
GPR119 Q8TDV5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730506 0.86 HSD11B1 (0.46) HSD11B1CPT1ACPT2CNR1CNR2
SCHEMBL30730608 0.85 HSD11B1 (0.44) HSD11B1CPT1ACPT2CNR1CNR2
SCHEMBL30730628 0.83 CPT1A (0.44) HSD11B1CPT1ACPT2CNR1CNR2
SCHEMBL30730687 0.83 PKM (0.43) HSD11B1CPT1ACPT2LMNAALDH1A1
SCHEMBL30730502 0.82 HSD11B1 (0.46) HSD11B1CPT1ACPT2CNR1CNR2
SCHEMBL30730447 0.81 LMNA (0.42) HSD11B1LMNAALDH1A1ALOX15TSHR
SCHEMBL30730464 0.80 HSD11B1 (0.46) HSD11B1CPT1ACPT2CNR1CNR2
SCHEMBL30730629 0.79 HSD11B1 (0.44) HSD11B1CPT1ACPT2CNR1CNR2
SCHEMBL30730713 0.79 LMNA (0.68) LMNAALDH1A1MAPTHTTSMN1; SMN2
SCHEMBL30730516 0.77 LMNA (0.40) HSD11B1LMNAALDH1A1ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 HSD11B1 235/4885CPT1A 227/4885CPT2 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.